Novel Mechanism of Action: Epetraboran, their lead candidate, is a novel boron-containing oral agent that targets leucyl-tRNA synthetase, a new mechanism for treating mycobacterial infections, potentially overcoming existing drug resistance.

Addressing Unmet Medical Need: Focused on *Mycobacterium avium* complex (MAC) lung disease, a serious, chronic, and difficult-to-treat infection with limited safe and effective oral therapies, positioning them to fill a significant market gap.

Oral Administration Advantage: Epetraboran's oral formulation offers a significant convenience advantage over often intravenous or poorly tolerated existing therapies, potentially improving patient adherence and quality of life.